original ) (raw )A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection
Joseph Beyene
BMC infectious …, 2009
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants
Meri Gorgievski-Hrisoho
Swiss medical weekly, 2001
View PDFchevron_right
A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the
Konstantin Gudkov
2012
View PDFchevron_right
Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Neal Thomas
Biologics Targets Therapy, 2007
View PDFchevron_right
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
Lim Kai Toh
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalizations for respiratory syncytial virus in infants
Meri Gorgievski-hrisoho , Andrea Duppenthaler
Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
Andrea Duppenthaler
Swiss Medical Weekly, 2001
View PDFchevron_right
Palivizumab in the prophylaxis of respiratory syncytial virus infection
silvia cardenas
Expert Review of Anti-infective Therapy, 2005
View PDFchevron_right
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
Antonio Boldrini
Italian Journal of Pediatrics, 2015
View PDFchevron_right
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
Giacomo Faldella , Edgardo Szyld
PEDIATRICS, 2009
View PDFchevron_right
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
Asunción Mejías
Biologics: targets & therapy, 2008
View PDFchevron_right
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
brian harris
BMC Pediatrics, 2010
View PDFchevron_right
A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
Konstantin Gudkov
BMC Research Notes, 2012
View PDFchevron_right
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATION TRIAL OF A HUMANIZED RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL ANTIBODY (MEDI-493) IN HIGH RISK INFANTS. • 768
Cori Daines
Pediatric Research, 1997
View PDFchevron_right
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
Nusrat Homaira
International Journal of Pediatrics, 2014
View PDFchevron_right
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Sinsi Hernández-Cancio
PEDIATRICS
View PDFchevron_right
Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
Copley Forbes
Human vaccines & immunotherapeutics, 2014
View PDFchevron_right
Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
Allison Callejas
PloS one, 2017
View PDFchevron_right
Palivizumab Prophylaxis of Respiratory Syncytial Virus Infection in High‐Risk Infants: A Note of Caution
Laurie Debonnett
Journal of Paediatrics and Child Health, 2003
View PDFchevron_right
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
Amanda Burls
Health technology assessment (Winchester, England), 2008
View PDFchevron_right
Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
Carlotta Biagi
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease
Robert Welliver
Antimicrobial agents and chemotherapy, 1999
View PDFchevron_right
Palivizumab for preventing respiratory syncytial virus (RSV) infection in children
CAMILA MICAELA ESCOBAR LIQUITAY
Cochrane Database of Systematic Reviews, 2020
View PDFchevron_right
Respiratory syncytial virus prophylaxis—the story so far
Jessie Groothuis
Respiratory Medicine, 2002
View PDFchevron_right